Skip to main content
Government of Quebec
Institut national de santé publique du Québec
Français
FR
Home
Navigation principale
The Institute
The Institute
About us
About us
Products and services offered
Back
Contact us
Contact us
Workplaces
Back
Exit
Back
Expertise
Expertise
Information management and analysis
Information management and analysis
Deprivation
Deprivation
Indices of multiple and multidimensional deprivation
Material and Social Deprivation Index
Back
Back
Individual and community development
Individual and community development
Perinatal and early childhood
Perinatal and early childhood
From Tiny Tot to Toddler
Back
Back
Lifestyles
Lifestyles
Alimentation
Alimentation
Health-promoting environments
Back
Back
Psychoactive substances, tobacco and gambling
Psychoactive substances, tobacco and gambling
Drugs and medicines
Drugs and medicines
Opioid overdoses
Back
Tobacco and electronic cigarettes
Tobacco and electronic cigarettes
Science Watch : Tobacco Control
Back
Back
Infectious diseases
Infectious diseases
Respiratory infectious diseases
Respiratory infectious diseases
Données des virus respiratoires
COVID-19 (coronavirus)
Back
Prevention and control of healthcare-associated infections
Prevention and control of healthcare-associated infections
Nosocomial infections
Back
Travel-health
Travel-health
Health tips for travellers
Back
Zoonoses and emerging diseases
Zoonoses and emerging diseases
Diseases transmitted by ticks
Back
Back
Occupational health
Occupational health
Work-related respiratory diseases
Work-related respiratory diseases
Asbestos
Back
Psychosocial risks in the workplace
Psychosocial risks in the workplace
Let's get started
Back
Back
Indigenous Health
Indigenous Health
Research Monitoring
Research Monitoring
Methodology for Indigenous Health Research Monitoring
Back
Nunavik Inuit Health Survey 2004
Back
Environmental Health
Environmental Health
Air quality
Air quality
Indoor air
Back
Back
Safety, violence and injury prevention
Safety, violence and injury prevention
Community safety promotion
Community safety promotion
Methods and tools
Back
Prevention of interpersonal violence
Prevention of interpersonal violence
Sexual Violence
Rapport québécois sur la violence et la santé
Back
Back
Exit
Back
Services
Services
Centre de toxicologie du Québec
Centre de toxicologie du Québec
About the CTQ
About the CTQ
Contact us
Back
Services
Services
Test catalog
Analysis request forms
Shipping samples
PayPal Bill Payment
Back
External quality assessment schemes
External quality assessment schemes
AMAP: AMAP Ring Test for Persistent Organic Pollutants in Human Serum
Creatinine: Interlaboratory Comparison Program for Measurement of Serum Creatinine
OSEQAS: External Quality Assessment Scheme for Organic Substances in Urine
PCI: Interlaboratory Comparison Program for Metals in Biological Matrices
QMEQAS: Quebec Multielement External Quality Assessment Scheme
Back
Back
Infectious diseases
Infectious diseases
Blood-Borne Infection Risk Assessment Unit
Blood-Borne Infection Risk Assessment Unit
Risk Assessment Process
Rights and Responsibilities
Back
Back
Exit
Back
Publications
Publications
Publications
Subscribe to INSPQ's mailing lists
Exit
Back
Surveys
Surveys
Respiratory viruses survey
Exit
Back
Danger page
Search
Search by keywords
Content type
Content type
Data
Internship
Laboratory analysis
News
Newsletter
Page
Publication
Tiny Tot
Training
Gaston De Serres
Publications
INSPQ
2022
Vaccination contre l’hépatite virale A suite à une éclosion à Nunavik
Administration d’une dose de vaccin bivalent aux personnes vaccinées avec le vaccin monovalent contre la COVID-19 depuis le 15 août 2022
Vaccination contre l’influenza et la COVID-19 à l’automne 2022
Stratégie vaccinale contre la COVID-19 à préconiser au Québec en 2022 et pertinence d’une 2e dose de rappel pour certains groupes vulnérables
Administration des doses subséquentes d’un vaccin contre la COVID-19 chez les personnes ayant développé une péricardite ou une myocardite
Enquête épidémiologique sur les travailleurs de la santé atteints par la COVID-19
2020
Critère de délai d’apparition des manifestations cliniques d’allure allergique suivant la vaccination pour lesquelles une consultation avec un spécialiste est recommandée avant la revaccination
Administration des IgIV en post-exposition contre la rougeole chez les personnes immunodéprimées et les femmes enceintes considérées non protégées
Maintien des groupes ciblés dans le cadre du Programme d’immunisation contre l’influenza du Québec (PIIQ) dans le contexte de la COVID-19
Les activités de vaccination en période de pandémie de COVID-2019 - Version 2.0 du 6 mai 2020
Utilisation du vaccin antigrippal Flucelvax produit sur lignée cellulaire
Portrait de la maladie à coronavirus 2019 (COVID-19) chez les résidents des centres d’hébergement et de soins de longue durée (CHSLD) du Québec
COVID-19 : Étude de séroprévalence chez des travailleurs de la santé de centres hospitaliers au Québec
Enquête épidémiologique sur les travailleurs de la santé atteints par la COVID-19 au printemps 2020
La surveillance des manifestations cliniques inhabituelles survenant après la vaccination au Québec
2025
Affection post-COVID-19 chez le personnel de la santé du Québec : Impact fonctionnel - Phase 1 : mai – juillet 2023
2024
Affection post-COVID-19 chez le personnel de la santé du Québec : fréquence, évolution et facteurs de risque
Myocardites ou péricardites à la suite de la vaccination contre la COVID-19
2023
Accidents vasculaires cérébraux suivant l’administration d’un vaccin contre la COVID-19
Zona survenu à la suite de la vaccination contre la COVID-19 au Québec
Paralysie de Bell survenue à la suite de la vaccination contre la COVID-19 au Québec
Manifestations cliniques indésirables à la suite de la vaccination de base contre la COVID-19 déclarées au système de surveillance passive du Québec
Surveillance active de la sécurité des trois premières doses de vaccin contre la COVID-19 au Québec
Administration de doses de rappel du vaccin contre la COVID-19 : recommandations pour l’hiver et le printemps 2023
Administration of COVID-19 booster doses: Recommendations for winter and spring 2023
2021
Pertinence d’une dose de rappel d’un vaccin contre la COVID 19 pour les différentes catégories d’adultes au Québec
Sommaire sur la vigie des manifestations cliniques inhabituelles après la vaccination contre la COVID-19 au Québec déclarées dans le cadre de la surveillance passive
Vaccination des personnes de moins de 30 ans contre la COVID-19 dans le contexte de la survenue de myocardites et péricardites après l’administration des vaccins à ARN messager
Pertinence d’une dose de vaccin à ARN messager contre la COVID-19 chez les personnes ayant reçu un vaccin à vecteur viral pour la série primaire
Intervalle entre les doses de la primovaccination avec les vaccins à ARN messager contre la COVID-19
Efficacité d’une dose de vaccin contre la COVID-19 chez les personnes de 60 ans et plus vivant dans la communauté au Québec
Impact de la première dose de vaccin contre la COVID-19 dans les CHSLD et les RPA
Définitions provisoires des cas de réinfection par le SRAS-CoV-2 à des fins de vigie
Étude sur la couverture vaccinale des enfants québécois âgés de 1 an, 2 ans et 7 ans en 2019
Enquête épidémiologique sur les travailleurs de la santé atteints par la COVID-19 entre le 12 juillet 2020 et le 16 janvier 2021
Étude sur la détresse psychologique des travailleurs de la santé atteints de la Covid-19 au Québec durant la deuxième vague pandémique
2019
Enquête sur la couverture vaccinale des enfants québécois pour les vaccins administrés avant l’entrée scolaire, 2017
Maladies évitables par la vaccination à déclaration obligatoire au Québec : rapport de surveillance 2014-2017
Choix des vaccins à utiliser dans le programme de vaccination contre l’influenza au Québec
Impact épidémiologique de la campagne de vaccination contre le méningocoque de sérogroupe B dans la région du Saguenay–Lac-Saint-Jean, en 2014 : rapport au 30 juin 2018
2018
Enquête épidémiologique sur l’association entre le vaccin Bexsero et le syndrome néphrotique
Enquête sur la couverture vaccinale des enfants de 1 an et 2 ans au Québec en 2016
2017
Rapport de l’enquête épidémiologique sur l’augmentation des réactions locales importantes et des cellulites à la suite de l’administration des vaccins ProQuad et Infanrix hexa
2016
Épidémiologie descriptive des maladies à déclaration obligatoire évitables par la vaccination au Québec, 2011-2013
Rapport final de surveillance de la sécurité de la vaccination des jeunes de 20 ans et moins contre le méningocoque de sérogroupe B au Saguenay–Lac-Saint-Jean
Estimation des hospitalisations attribuables à l’influenza selon différentes méthodes
2015
Résultats de la surveillance de la sécurité des première et deuxième doses du vaccin contre le méningocoque de sérogroupe B administré au Saguenay–Lac-Saint-Jean
Couverture vaccinale et âge à la vaccination avant l'éclosion de rougeole de 2011 au Québec et impact de l'Opération rougeole
2014
Initial Dose of a Multicomponent Serogroup B Meningococcal Vaccine in the Saguenay–Lac-Saint-Jean Region, Québec, Canada: An Interim Safety Surveillance Report
Rapport intérimaire de surveillance de la sécurité de la première dose du vaccin contre le méningocoque de sérogroupe B au Saguenay–Lac-St-Jean
2013
Risque de survenue du syndrome de Guillain-Barré à la suite de l'administration de vaccins pandémiques A(H1N1) durant l'automne 2009 dans la province de Québec
2011
Fardeau de la varicelle et du zona au Québec, 1990-2008 : impact du programme universel de vaccination
2009
Avis sur le retrait préventif en milieux scolaires de la travailleuse enceinte en lien avec la grippe pandémique (H1N1) 2009
2005
Protection contre l'hépatite A et B conférée par deux doses de Recombivax 2,5 μg ou deux doses de Twinrix junior chez des enfants âgés de 8 à 10 ans
Utilisation du vaccin acellulaire contre la coqueluche chez les adolescents et les adultes québécois
Scientific papers
2025
New-onset anesthesia/paresthesia following the administration of COVID-19 vaccines in Quebec, Canada
Using machine learning for personalized prediction of longitudinal coronavirus disease 2019 vaccine responses in transplant recipients
2024
mRNA COVID-19 vaccine safety among children and adolescents: a Canadian National Vaccine Safety Network cohort study
Increasing our knowledge about the epidemiology of Helicobacter pylori in Nunavik's Inuit population (Québec, Canada) using Qanuilirpitaa? 2017 cross-sectional survey
Participant-reported neurological events following immunization in the Canadian National Vaccine Safety Network-COVID-19 vaccine (CANVAS-COVID) study
Omicron incidence and seroprevalence among children in Montreal, Canada, in early 2023: final results from the longitudinal EnCORE serology study
SARS-CoV-2 seroprevalence and mental health of school staff: a cross-sectional study of schools from four areas of Montreal, Quebec in 2021
Incidence of SARS-CoV-2 during the Omicron wave: Results of a longitudinal serosurvey in Québec, Canada
A multiprovincial retrospective analysis of the incidence of myocarditis or pericarditis after mRNA vaccination compared to the incidence after SARS-CoV-2 infection
Pre-Omicron seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and teenagers in Montreal, Canada
2023
Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination
BNT162b2 effectiveness against Delta and Omicron variants of SARS-CoV-2 in adolescents aged 12-17 years, by dosing interval and duration
A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses
2022
Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada
Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study
Risk and protective factors for SARS-CoV-2 infection among healthcare workers: a test-negative case-control study in Quebec, Canada
Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study
Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study
Time trends in social contacts before and during the COVID-19 pandemic: the CONNECT study
Time trends in social contacts of individuals according to comorbidity and vaccination status, before and during the COVID-19 pandemic
Case Report: Acute Necrotizing Encephalopathy Following COVID-19 Vaccine
Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada
Impact of the first vaccine dose on COVID-19 and its complications in long-term care facilities and private residences for seniors in Québec, Canada
Seroprevalence of SARS-CoV-2 antibodies among blood donors in Québec: an update from a serial cross-sectional study
Séroprévalence du SRAS-CoV-2 chez les travailleurs de la santé de 10 hôpitaux du Québec, au Canada: étude transversale
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses
Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses
Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine
Persisting chemosensory impairments in 366 healthcare workers following COVID-19: an 11-month follow-up
SARS-CoV-2 seroprevalence in health care workers from 10 hospitals in Quebec, Canada: a cross-sectional study
2021
Persistence of Infectivity in Elderly Individuals Diagnosed with SARS-CoV-2 Infection 10 Days after Onset of Symptoms: A Cross-Sectional Study
Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada
Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada
Chemosensory dysfunctions induced by COVID-19 can persist up to 7 months: A study of over 700 healthcare workers
Epidemiology associated with the exposure to Toxoplasma gondii in Nunavik's Inuit population using the 2017 Qanuilirpitaa cross-sectional health survey
Seroprevalence of anti-SARS-CoV-2 antibodies among school and daycare children and personnel: protocol for a cohort study in Montreal, Canada
A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses
SARS-CoV-2 seroprevalence among blood donors in Québec, and analysis of symptoms associated with seropositivity: a nested case-control study
Characterization and evolution of infection control practices among SARS-CoV-2 infected healthcare workers of acute care hospitals and long-term care facilities in Quebec, Canada, Spring 2020
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Infectivity of Healthcare Workers Diagnosed with SARS-CoV-2 Infection Approximately 2 weeks after Onset of Symptoms: a Cross-Sectional Study
Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada
2020
Influenza Vaccine Does Not Increase the Risk of Coronavirus or Other Noninfluenza Respiratory Viruses: Retrospective Analysis From Canada, 2010-2011 to 2016-2017
Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis
Influenza vaccine effectiveness by A(H3N2) phylogenetic sub-cluster and prior vaccination history: 2016-17 and 2017-18 epidemics in Canada
Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020
Quantification of the total neuraminidase content of recent commercially-available influenza vaccines: Introducing a neuraminidase titration reagent
2019
Evidence in a Cluster Randomized Controlled Trial of Increased 2009 Pandemic Risk Associated With 2008-2009 Seasonal Influenza Vaccine Receipt
Impact of the adolescent pertussis booster dose on the incidence of pertussis in British Columbia and Quebec, Canada
A mixed vaccination schedule of HPV vaccine induces a 100% seropositivity to all 9 HPV types included in 9vHPV vaccine
Letter to the editor: Measles outbreak in Gothenburg urban area, Sweden, 2017 to 2018: low viral load in breakthrough infections
Nephrotic syndrome following four-component meningococcal B vaccination: Epidemiologic investigation of a surveillance signal
Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch
Vaccine Effectiveness Against Lineage-matched and -mismatched Influenza B Viruses Across 8 Seasons in Canada, 2010-2011 to 2017-2018
Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials
Children under 10 years of age were more affected by the 2018/19 influenza A(H1N1)pdm09 epidemic in Canada: possible cohort effect following the 2009 influenza pandemic
Rate of Recurrence of Adverse Events Following Immunization: Results of 19 Years of Surveillance In Quebec, Canada
Respiratory syncytial virus contributes to more severe respiratory morbidity than influenza in children < 2 years during seasonal influenza peaks
Caution required in the use of administrative data and general laboratory submissions for influenza vaccine effectiveness estimation
Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019
Assessment of naturally acquired neutralizing antibodies against rabies Lyssavirus in a subset of Nunavik's Inuit population considered most at risk of being exposed to rabid animals
Application of the Test-Negative Design to General Laboratory Submissions
2018
Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada
Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial
Should Sex Be Considered an Effect Modifier in the Evaluation of Influenza Vaccine Effectiveness?
Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa®) and MMRV (ProQuad®) at 18 months of age
Impact of the addition of new vaccines in the early childhood schedule on vaccine coverage by 24 months of age from 2006 to 2016 in Quebec, Canada
Role of egg-adaptation mutations in low influenza A(H3N2) vaccine effectiveness during the 2012-13 season
Ecological Fallacy, Nonspecific Outcomes, and the Attribution of Disproportionate Vaccine Benefits
Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018
Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada
Absence of association between Guillain-Barré syndrome hospitalizations and HPV-vaccine
Selection bias in the assessment of frailty and its role in influenza vaccine effectiveness evaluation among elderly adults.
2017
Adverse events following live-attenuated intranasal influenza vaccination of children with cystic fibrosis: Results from two influenza seasons.
Age-Related Differences in Influenza B Infection by Lineage in a Community-Based Sentinel System, 2010-2011 to 2015-2016, Canada.
Evaluation of the New World Health Organization Case Definition of Severe Acute Respiratory Infection for Influenza Surveillance During the Peak Weeks of Two Influenza Seasons in Quebec, Canada.
Risk of Recurrence of Adverse Events Following Immunization: A Systematic Review.
Reply to Chung et al.
Viral interference and the live-attenuated intranasal influenza vaccine: Results from a pediatric cohort with cystic fibrosis.
Clinical Approach Used in Medical Consultations for Allergic-Like Events Following Immunization: Case Series Report in Relation to Practice Guidelines.
Reduced antibody response to infant measles vaccination: effects based on type and timing of the first vaccine dose persist after the second dose.
RE: "Detectable Risks in Studies of the Fetal Benefits of Maternal Influenza Vaccination"
Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.
Serial Vaccination and the Antigenic Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2) Epidemics in Canada, 2010-2011 to 2014-2015.
RE: "DETECTABLE RISKS IN STUDIES OF THE FETAL BENEFITS OF MATERNAL INFLUENZA VACCINATION"
Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017.
Influenza Vaccination of Healthcare Workers: Critical Analysis of the Evidence for Patient Benefit Underpinning Policies of Enforcement.
Prevalence of risk factors for acquiring measles during the 2011 outbreak in Quebec and impact of the province-wide school-based vaccination campaign on population immunity.
Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada
Selection Bias in the Assessment of Frailty and Its Role in Influenza Vaccine Effectiveness Evaluation Among Elderly Adults
Repeat Influenza Vaccination and High-Dose Efficacy.
2016
Influenza Virus Detection Following Administration of Live-Attenuated Intranasal Influenza Vaccine in Children With Cystic Fibrosis and Their Healthy Siblings.
Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study.
A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season.
The accuracy and timeliness of neuraminidase inhibitor dispensing data for predicting laboratory-confirmed influenza.
Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.
Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season
2015
Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors.
Dramatic reduction in hepatitis B through school-based immunization without a routine infant program in a low endemicity region.
Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada
Measles in Canada Between 2002 and 2013.
Pre- and postpandemic estimates of 2009 pandemic influenza A(H1N1) seroprotection to inform surveillance-based incidence, by age, during the 2013-2014 epidemic in Canada
Mid-Season Estimates of Influenza Vaccine Effectiveness against Influenza A(H3N2) Hospitalization in the Elderly in Quebec, Canada, January 2015.
Selection bias in the comparison between adjuvanted and unadjuvanted influenza vaccine effectiveness
2014
Other respiratory viruses are important contributors to adult respiratory hospitalizations and mortality even during peak weeks of the influenza season
Human metapneumovirus viral load is an important risk factor for disease severity in young children
Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses
Measles in children vaccinated with 2 doses of MMR
2013
The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials
Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine
Largest measles epidemic in North America in a decade--Quebec, Canada, 2011: contribution of susceptibility, serendipity, and superspreading events
Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine
Higher risk of measles when the first dose of a 2-dose schedule of measles vaccine is given at 12-14 months versus 15 months of age
2012
Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period
Effectiveness of pandemic H1N1 vaccine against influenza-related hospitalization in children
2011
Contagious period for pandemic (H1N1) 2009
2010
Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine
In memoriam, Bernard Duval (1949-2008)
2009
Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given 5 or 10 years later
Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations
The need for validation of statistical methods for estimating respiratory virus-attributable hospitalization
Bats in the bedroom, bats in the belfry: reanalysis of the rationale for rabies postexposure prophylaxis
Bat rabies in the United States and Canada from 1950 through 2007: human cases with and without bat contact
2008
Population-based survey of travel patterns among Canadians visiting hepatitis A-endemic countries
2007
Trends of hepatitis A hospitalization and risk factors in Quebec, Canada, between 1990 and 2003
Impact of the quebec school-based hepatitis B immunization program and potential benefit of the addition of an infant immunization program
2006
Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children
2005
Nationwide canadian study of hepatitis a antibody prevalence among children eight to thirteen years old
Oculo-respiratory syndrome after influenza vaccination: trends over four influenza seasons
Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country
Recurrence risk of oculorespiratory syndrome after influenza vaccination: randomized controlled trial of previously affected persons
2004
Risk and prevention of meningococcal disease among education workers: A review
Why are some children incompletely vaccinated at the age of 2?
2003
A population-based comparison between travelers who consulted travel clinics and those who did not
Preadolescent non- and hyporesponders following three doses of hepatitis B vaccine need only one more dose
2002
Ineffectiveness of the current strategy to prevent hepatitis A in travelers
Most ten-year-old children with negative or unknown histories of chickenpox are immune
2001
Effectiveness of a single dose of acellular pertussis vaccine to prevent pertussis in children primed with pertussis whole cell vaccine
Lack of conviction about vaccination in certain Quebec vaccinators
Importance of attributable risk in monitoring adverse events after immunization: hepatitis B vaccination in children
Molecular Confirmation of Hepatitis A Virus from Well Water: Epidemiology and Public Health Implications
1999
Feasibility and ethical issues: experiences and concerns of healthcare workers regarding a new RSV prophylaxis programme in Nunavik, Quebec
Others
2020
Safety of co-administration of COVID-19 and seasonal influenza vaccines in individuals with autoimmune diseases from the Canadian National Vaccine Safety Network
Government of Quebec
Government of Quebec
